Factory 99% Emtricitabine Powder CAS 143491-57-0 Chemical Intermediate Emtricitabine

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A896
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Emtricitabine
• CAS: 143491-57-0
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Emtricitabine
Appearance	White Powder
CAS NO.	143491-57-0
Storage	Keep in a cool, dry, dark location

 

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that exhibits antiviral activity against HIV-1 and hepatitis B virus (HBV). 

 

1. HIV-1 Treatment: Emtricitabine is commonly used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and adolescents. It helps to suppress viral replication and reduce the risk of disease progression.

2. HBV Treatment: Emtricitabine may also be used in combination with other antiviral agents for the treatment of chronic HBV infection. It helps to inhibit viral replication and potentially improve liver function.

3. PrEP and PEP: In addition to its use in HIV-1 treatment, emtricitabine can be used as part of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) regimens to prevent HIV-1 infection in individuals at high risk of acquiring the virus.

1. HIV-1 Inhibition: Emtricitabine works by inhibiting the HIV-1 reverse transcriptase enzyme, which is essential for the virus to replicate its genetic material. By blocking this enzyme, emtricitabine prevents the virus from producing new copies of itself, thereby reducing viral load and slowing disease progression.

2. HBV Inhibition: Similarly, emtricitabine inhibits the HBV reverse transcriptase enzyme, preventing the virus from replicating its DNA. This can help to suppress viral replication and reduce liver inflammation and damage in individuals with chronic HBV infection.

3. Combination Therapy: Emtricitabine is often used in combination with other antiretroviral agents to enhance its efficacy and reduce the risk of viral resistance. Combination therapy allows for the targeting of multiple steps in the viral replication cycle, making it more difficult for the virus to develop resistance.